NasdaqGS:AMGNBiotechs
Amgen (AMGN) Beat Revenue Forecasts, Is The Stock Overvalued?
Amgen (AMGN) is back in focus after quarterly revenue of $8.62b surpassed analyst forecasts, with management pointing to double digit growth across 16 brands and reaffirming confidence in its long term outlook.
See our latest analysis for Amgen.
Against this backdrop, Amgen’s recent momentum has been firm. A 10.54% 90 day share price return and a 26.34% 1 year total shareholder return suggest investors are responding positively to earnings delivery and the company’s pipeline progress.
If you...